Image 1
Beyond Air’s LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure
28 juin 2022 16h05 HE | Beyond Air™
First and only nitric oxide generator and delivery system indicated for the treatment of term and near-term neonates with hypoxic respiratory failure that uses ambient air to provide unlimited,...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th
14 juin 2022 16h30 HE | Beyond Air™
GARDEN CITY, New York, June 14, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Cancer™ Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer
01 juin 2022 07h00 HE | Beyond Air™
Dr. Monson is a board-certified radiation oncologist and brings over 25 years of clinical oncology experience to Beyond Cancer. Dr. Monson is a founding partner and President of California Cancer...
Methemoglobin (MetHb) and Nitrogen Dioxide (NO2) Levels (<10% and <5 ppm, respectively are safe)*
Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022
17 mai 2022 16h05 HE | Beyond Air™
A total of 2,323 inhalations have been self-administered at home to date with no treatment related discontinuations reported and overall high treatment compliance All subjects have successfully...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer
17 mai 2022 07h00 HE | Beyond Air™
HAMILTON, Bermuda, May 17, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration nitric oxide (UNO) for...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast
16 mai 2022 07h05 HE | Beyond Air™
GARDEN CITY, N.Y., May 16, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022
25 avr. 2022 16h05 HE | Beyond Air™
GARDEN CITY, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022
25 avr. 2022 07h00 HE | Beyond Air™
Inhaled NO treatment in patients hospitalized with COVID-19 and other community-acquired viral pneumonia was well tolerated overall, and safe, with improved efficacy parameters as compared to standard...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Air® to Participate in Three Upcoming Medical Conferences
18 avr. 2022 07h00 HE | Beyond Air™
GARDEN CITY, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond-Air-The-Magic-of-Breathing.png
Beyond Cancer™ Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect
11 avr. 2022 07h00 HE | Beyond Air™
Data suggests ultra-high concentration gaseous NO (gNO) induced both innate and adaptive immune cell populations, and a decline in immune suppressor cells, which are indicative of an anti-tumor immune...